Zuclopenthixol
- PDF / 141,170 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 113 Downloads / 143 Views
1
S
Neuroleptic malignant syndrome: case report A 38-year-old man developed neuroleptic malignant syndrome (NMS) during treatment with zuclopenthixol for schizophrenia [duration of treatment not stated]. The man was hospitalised with fever of 39.6°C, hypersalivation, dysphagia, dyspnoea, dysarthria, tachycardia and muscle rigidity. Due to acute psychotic episodes, he had been given oral zuclopenthixol acetate 50 mg/mL twice over the preceding 3 days, instead of IM injections. He was lethargic on examination, with bilateral muscle rigidity and akinesia. Laboratory investigations showed the following: WBC count 12 700, CPK 3226 U/L, BUN 74 mg/dL and creatinine 1.4 mg/dL. The man was hydrated, and his electrolyte imbalances were corrected. His antipsychotic therapy was discontinued, and he received lorazepam for agitation. His WBC count, CPK and BUN levels and muscle rigidity started to improve on day 3. NMS had resolved on day 10. Yac? H, et al. Neuroleptic Malignant Syndrome: a Case Report. 15th Congress of the European Federation of Neurological Societies : abstr. P1649, 10 Sep 2011. 803060910 Available from: URL: http://efns2011.efns.org [abstract] - Turkey
0114-9954/10/1371-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 1 Oct 2011 No. 1371
